291 related articles for article (PubMed ID: 30556435)
1. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials.
Fujimura T; Hidaka T; Kambayashi Y; Aiba S
Expert Opin Investig Drugs; 2019 Feb; 28(2):143-148. PubMed ID: 30556435
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
3. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
4. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase inhibitors in melanoma.
Eigentler TK; Meier F; Garbe C
Expert Opin Pharmacother; 2013 Nov; 14(16):2195-201. PubMed ID: 23992377
[TBL] [Abstract][Full Text] [Related]
7. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
8. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
9. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
10. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
Jang S; Atkins MB
Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
[TBL] [Abstract][Full Text] [Related]
11. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
King JW; Nathan PD
Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
14. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
16. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
17. Improving patient outcomes to targeted therapies in melanoma.
Eroglu Z; Smalley KS; Sondak VK
Expert Rev Anticancer Ther; 2016 Jun; 16(6):633-41. PubMed ID: 27137746
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
19. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
20. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
